Abstract
Determination of protective efficacy after natural rotavirus infection is important as a basis for evaluating rotavirus vaccines. Therefore, placebo recipients in a large 2-year rotavirus vaccine trial conducted across the United States were followed to determine the protection afforded by natural rotavirus infection. Serotype 1 rotaviruses predominated (93% year 1, 66% year 2), but isolates of all four majorhuman rotavirus serotypes circulated during both years. Of the 45 placebo recipients with documented rotavirus illnesses in year 1, 1 developed rotavirus disease in year 2 compared with 29 of the other 235 placebo recipients (P =.03). Serologic data were available for 171 placebo recipients, and 37 of 140 without rotavirus illnesses in year 1 had evidence of asymptomatic rotavirus infection. None of these 37 experienced rotavirus disease in year 2 compared with 22 ofthe remaining 103 (P <.001). Overall efficacy after natural rotavirus infection was 93% (95% confidence interval, 50%-99%).
Original language | English (US) |
---|---|
Pages (from-to) | 900-904 |
Number of pages | 5 |
Journal | Journal of Infectious Diseases |
Volume | 169 |
Issue number | 4 |
DOIs | |
State | Published - Apr 1994 |
ASJC Scopus subject areas
- Immunology and Allergy
- Infectious Diseases